NeoGenomics EVP converts RSUs, withholds shares
NeoGenomics, Inc. executive Alicia C. Olivo, EVP, GC & Business Development, reported equity award activity on May 11, 2026.
Rhea-AI Filing Summary
NeoGenomics, Inc. executive Alicia C. Olivo, EVP, GC & Business Development, reported equity award activity on May 11, 2026. She converted 3,944 restricted stock units into an equal number of common shares, and 2,559 common shares were disposed of under code F to satisfy exercise price or tax obligations. She continues to hold multiple stock option, restricted stock unit and performance stock unit awards, including options on 107,450 shares at $13.05 expiring in 2035 and 147,804 shares at $10.81 expiring in 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
3,944 shares exercised/converted
Exercise
19 txns
Insider
Olivo Alicia C
Role
EVP, GC & Business Development
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 3,944 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,944 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 2,559 | $0.00 | $0.00 |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 201,556 contracts for 198,997 underlying shares (Direct);
Common Stock — 93,567 shares (Direct);
Stock Option (Right to Buy) — 406,386 contracts (Direct);
Performance Stock Unit — 44,838 contracts (Direct)
Footnotes (19)
- F1. On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- F2. Once vested, the shares of common stock are not subject to expiration.
- F3. On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F4. On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F5. On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F6. On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F7. On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F8. On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F9. On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- F10. On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
- F11. On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- F12. On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
- F13. On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- F14. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
- F15. On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- F16. On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- F17. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%.
- F18. On March 1, 2026, Ms. Olivo was granted 147,804 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- F19. On March 1, 2026, Ms. Olivo was granted 89,013 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
Key Figures
RSUs converted to common stock: 3,944 shares
Shares disposed under code F: 2,559 shares
Option exercise price: $13.05
+5 more
8 metrics
RSUs converted to common stock
3,944 shares
Restricted stock units converted into common stock on May 11, 2026
Shares disposed under code F
2,559 shares
Common shares delivered or withheld for exercise price or taxes on May 11, 2026
Option exercise price
$13.05
Exercise price for options expiring February 21, 2035
Underlying shares at $13.05
107,450 shares
Stock options granted February 21, 2025, expiring 2035-02-21
Option exercise price
$10.81
Exercise price for options expiring March 1, 2036
Underlying shares at $10.81
147,804 shares
Stock options granted March 1, 2026, expiring 2036-03-01
Outstanding restricted stock units
89,013 units
Restricted stock units granted March 1, 2026
Performance stock units at target
25,330 units
Performance stock units granted February 23, 2024 at target performance
Key Terms
restricted stock units, performance stock units, premium-price stock option, weighted average price, +1 more
5 terms
restricted stock units financial
"On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance stock units financial
"On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest."
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
weighted average price financial
"based on the weighted average price of the Company's common stock over the 20-day trailing trading period."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
trailing trading period financial
"based on the weighted average price of the Company's common stock over the 20-day trailing trading period."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity award transaction did NeoGenomics (NEO) EVP Alicia C. Olivo report?
She reported converting 3,944 restricted stock units into common stock on May 11, 2026. In a related transaction, 2,559 common shares were disposed of under code F, reflecting shares delivered or withheld to cover the exercise price or related tax obligations.
What major stock option positions does NeoGenomics (NEO) EVP Alicia C. Olivo hold?
She holds stock options over 107,450 shares at a $13.05 exercise price expiring February 21, 2035. She also holds options over 147,804 shares at $10.81 expiring March 1, 2036, along with several smaller option grants at higher exercise prices.
What performance stock unit grants are disclosed for NeoGenomics (NEO) EVP Alicia C. Olivo?
Disclosed awards include 19,508 performance stock units from May 11, 2023 and 25,330 units from February 23, 2024 at target performance. Footnotes state maximum vesting of 29,262 and 37,996 shares respectively, tied to share price growth and revenue goals plus continued service.
Are the reported NeoGenomics (NEO) insider transactions under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan. Footnotes describing these awards do not reference Rule 10b5-1 or other pre-arranged trading plans, so the transactions are not identified as plan-based in this report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
